Information  X 
Enter a valid email address

Sareum Holdings PLC (SAR)

  Print      Mail a friend       Annual reports

Tuesday 24 April, 2018

Sareum Holdings PLC

Sareum to Present at BioTrinity 2018 in London

RNS Number : 8341L
Sareum Holdings PLC
24 April 2018
 

(AIM: SAR)                                                                                                                                          24 April 2018

Sareum Holdings PLC

("Sareum" or the "Company")

Sareum to Present at BioTrinity 2018 in London

Sareum Holdings plc (AIM:SAR), the specialist cancer drug discovery and development business, will present at BioTrinity 2018 in London today, at 12.20pm. Dr Tim Mitchell, CEO of Sareum, will introduce Sareum and provide an overview of its lead programmes including its most advanced programme SRA737, a novel Checkpoint kinase 1 (Chk1) inhibitor licensed to Sierra Oncology (NASDAQ: SRRA).

Presentation details are as follows:

Date: Tuesday 24 April 2018

Time: 12.20

Location: Plenary Hall Two, Novotel London West

BioTrinity is one of Europe's leading biopartnering and investment conferences, and the largest of its type in the UK. The event is attended by global life sciences investors, big pharma executives and emerging R&D companies. 

For further information, please contact: 

Sareum Holdings plc

 

Tim Mitchell

01223 497 700

WH Ireland Limited (Nominated Adviser and Co-Broker)

Chris Fielding / James Sinclair-Ford

020 7220 1666

Hybridan LLP (Co-Broker)

 

Claire Noyce

020 3764 2341

Citigate Dewe Rogerson (Media enquiries)

 

 Shabnam Bashir/ Mark Swallow/ David Dible

 020 7282 9571

Notes for editors: 

Sareum is a specialist drug discovery and development company delivering targeted small molecule therapeutics, focusing on cancer and autoimmune disease, and generating value through licensing them to international pharmaceutical and biotechnology companies at the preclinical or early clinical trials stage.

Its most advanced programme, SRA737, is a novel Checkpoint kinase 1 (Chk1) inhibitor licensed to NASDAQ-listed Sierra Oncology and in clinical trials targeting a range of advanced cancers. The key role of Chk1 in cancer cell replication and DNA damage repair suggests that SRA737 may have broad application as a targeted therapy in combination with other oncology and immune-oncology drugs in genetically defined patients.

Sareum is also advancing programmes to develop novel tyrosine kinase 2 (TYK2) inhibitors in autoimmune diseases and cancers, and Aurora+FLT3 inhibitors in haematological cancers, which are in the IND-enabling preclinical and lead optimisation stages.

The Company's drug discovery technology platform (SKIL® - Sareum Kinase Inhibitor Library) is being applied to generate drug research programmes against other kinase targets.

Sareum Holdings plc is listed on the AIM market of the London Stock Exchange, trading under the ticker SAR. For further information, please visit www.sareum.co.uk

- Ends -

 


This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
NRAEXLFLVZFXBBL

a d v e r t i s e m e n t